Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine



   non-alcoholic fatty liver disease
  

Disease ID 881
Disease non-alcoholic fatty liver disease
Definition
A term referring to fatty replacement of the hepatic parenchyma which is not related to alcohol use.
Synonym
fatty liver, nonalcoholic
fatty livers, nonalcoholic
liver, nonalcoholic fatty
livers, nonalcoholic fatty
nafld
nafld - nonalcoholic fatty liver disease
non alcoholic fatty liver disease
non-alcoholic fatty liver
non-alcoholic fatty liver (disorder)
non-alcoholic fatty liver disease [disease/finding]
nonalcoholic fatty liver
nonalcoholic fatty liver (disorder)
nonalcoholic fatty liver disease
nonalcoholic fatty livers
UMLS
C0400966
MeSH
SNOMED-CT
Comorbidity
UMLS | Disease | Sentences' Count(Total Sentences:118)
C0028754  |  obesity  |  164
C0948265  |  metabolic syndrome  |  102
C0011847  |  diabetes  |  88
C0011860  |  type 2 diabetes  |  82
C0011849  |  diabetes mellitus  |  37
C0011860  |  type 2 diabetes mellitus  |  36
C0004153  |  atherosclerosis  |  26
C0042373  |  vascular disease  |  21
C0023890  |  cirrhosis  |  21
C0007222  |  cardiovascular disease  |  20
C0023895  |  liver disease  |  18
C0010068  |  coronary artery disease  |  13
C0019204  |  hepatocellular carcinoma  |  13
C0019158  |  hepatitis  |  11
C0028754  |  adiposity  |  10
C0028756  |  morbid obesity  |  9
C0020538  |  hypertension  |  9
C0020676  |  hypothyroidism  |  8
C0032460  |  polycystic ovary  |  8
C0032460  |  polycystic ovary syndrome  |  8
C0018799  |  heart disease  |  7
C0019196  |  hepatitis c  |  6
C0042870  |  vitamin d defic  |  5
C0010068  |  coronary heart disease  |  5
C0740394  |  hyperuricemia  |  5
C0042870  |  vitamin d deficiency  |  5
C0020456  |  hyperglycemia  |  5
C0033860  |  psoriasis  |  4
C0019163  |  hepatitis b  |  4
C0023903  |  liver cancer  |  4
C0028756  |  severe obesity  |  4
C0022661  |  chronic kidney disease  |  4
C0020541  |  portal hypertension  |  4
C0271650  |  glucose intolerance  |  4
C0159069  |  impaired glucose tolerance  |  3
C0008350  |  gallstones  |  3
C0022658  |  kidney disease  |  3
C1302401  |  colorectal adenoma  |  3
C0007222  |  cardiovascular diseases  |  3
C0042373  |  vascular diseases  |  3
C0282193  |  iron overload  |  3
C0035309  |  retinopathy  |  3
C0011884  |  diabetic retinopathy  |  2
C0006142  |  breast cancer  |  2
C1561644  |  chronic kidney disease (ckd)  |  2
C0020459  |  hyperinsulinemia  |  2
C0009402  |  colorectal cancer  |  2
C0520679  |  obstructive sleep apnea  |  2
C0023890  |  liver cirrhosis  |  2
C0042769  |  virus infection  |  2
C0023895  |  liver diseases  |  2
C0037315  |  sleep apnea  |  2
C0007113  |  rectal cancer  |  2
C0271650  |  prediabetes  |  2
C0008350  |  gallstone  |  2
C0021053  |  immune dysfunction  |  1
C0021831  |  bowel disease  |  1
C0019196  |  viral hepatitis c  |  1
C1510471  |  vitamin deficiencies  |  1
C0008350  |  gall stone  |  1
C0022104  |  irritable bowel syndrome  |  1
C0020474  |  familial combined hyperlipidemia  |  1
C0008350  |  cholelithiasis  |  1
C0042373  |  vascular disorder  |  1
C0022658  |  nephropathy  |  1
C1510471  |  hypovitaminosis  |  1
C0041696  |  major depressive disorder  |  1
C0017178  |  gastrointestinal disorder  |  1
C0011881  |  diabetic nephropathy  |  1
C0037061  |  siderosis  |  1
C0040053  |  thrombosis  |  1
C0566602  |  primary sclerosing cholangitis  |  1
C1257763  |  overnutrition  |  1
C0031069  |  familial mediterranean fever  |  1
C0085207  |  gestational diabetes mellitus  |  1
C0017168  |  esophageal reflux  |  1
C0155765  |  microangiopathy  |  1
C0398623  |  thrombophilia  |  1
C0442874  |  neuropathy  |  1
C0023787  |  lipodystrophy  |  1
C0021390  |  inflammatory bowel disease  |  1
C0021670  |  insulinoma  |  1
C0017168  |  oesophageal reflux  |  1
C0085207  |  gestational diabetes  |  1
C0035078  |  renal failure  |  1
C0011860  |  niddm  |  1
C0011860  |  type ii diabetes  |  1
C0031117  |  peripheral neuropathy  |  1
C0007570  |  coeliac disease  |  1
C0003467  |  anxiety  |  1
C0013338  |  growth hormone deficiency  |  1
C0010054  |  coronary artery atherosclerosis  |  1
C0001622  |  hypercortisolism  |  1
C0034885  |  rectal neoplasms  |  1
C0008313  |  sclerosing cholangitis  |  1
C0017168  |  gastroesophageal reflux  |  1
C0851578  |  sleep disorders  |  1
C0007222  |  cardiovascular disorders  |  1
C0017178  |  gastrointestinal disorders  |  1
C0042373  |  vascular disorders  |  1
C0003873  |  rheumatoid arthritis  |  1
C0010481  |  cushing's syndrome  |  1
C0035579  |  hypovitaminosis d  |  1
C0010068  |  coronary disease  |  1
C0011882  |  diabetic neuropathy  |  1
C0022661  |  chronic renal failure  |  1
C0020538  |  high blood pressure  |  1
C0011860  |  diabetes mellitus type 2  |  1
C0850572  |  colonic adenoma  |  1
C0011570  |  depression  |  1
C0022104  |  irritable bowel  |  1
C0004153  |  atherosclerotic vascular disease  |  1
C0001430  |  adenoma  |  1
C1384514  |  primary aldosteronism  |  1
C0042721  |  viral hepatitis  |  1
C0149931  |  migraine  |  1
C0206081  |  hyperandrogenism  |  1
C0007570  |  celiac disease  |  1
Curated Gene
Entrez_id | Symbol | Resource(Total Genes:40)
3552  |  IL1A  |  CTD_human
2952  |  GSTT1  |  CTD_human
7040  |  TGFB1  |  CTD_human
5244  |  ABCB4  |  CTD_human
929  |  CD14  |  CTD_human
2147  |  F2  |  CTD_human
23411  |  SIRT1  |  CTD_human
1586  |  CYP17A1  |  CTD_human
6720  |  SREBF1  |  CTD_human
3565  |  IL4  |  CTD_human
1636  |  ACE  |  CTD_human
25813  |  SAMM50  |  GWASCAT
8517  |  IKBKG  |  CTD_human
1437  |  CSF2  |  CTD_human
2944  |  GSTM1  |  CTD_human
80339  |  PNPLA3  |  CTD_human;GWASCAT
3562  |  IL3  |  CTD_human
2950  |  GSTP1  |  CTD_human
2938  |  GSTA1  |  CTD_human
4312  |  MMP1  |  CTD_human
355  |  FAS  |  CTD_human
3949  |  LDLR  |  CTD_human
5897  |  RAG2  |  CTD_human
9370  |  ADIPOQ  |  CTD_human
7133  |  TNFRSF1B  |  CTD_human
506  |  ATP5B  |  CTD_human
5465  |  PPARA  |  CTD_human
5551  |  PRF1  |  CTD_human
284217  |  LAMA1  |  CTD_human
5055  |  SERPINB2  |  CTD_human
29780  |  PARVB  |  GWASCAT
27087  |  B3GAT1  |  CTD_human
3952  |  LEP  |  CTD_human
4780  |  NFE2L2  |  CTD_human
3976  |  LIF  |  CTD_human
949  |  SCARB1  |  CTD_human
7494  |  XBP1  |  CTD_human
5467  |  PPARD  |  CTD_human
53345  |  TM6SF2  |  CTD_human
8614  |  STC2  |  CTD_human
Inferring Gene
Entrez_id | Symbol | Resource(Total Genes:83)
33  |  ACADL  |  CIPHER
35  |  ACADS  |  CIPHER
453  |  ASS1P8  |  CIPHER
53335  |  BCL11A  |  CIPHER
781  |  CACNA2D1  |  CIPHER
1000  |  CDH2  |  CIPHER
60680  |  CELF5  |  CIPHER
9435  |  CHST2  |  CIPHER
246714  |  CKS1BP2  |  CIPHER
1305  |  COL13A1  |  CIPHER
91351  |  DDX60L  |  CIPHER
254102  |  EHBP1L1  |  CIPHER
114182  |  FAM8A6P  |  CIPHER
10160  |  FARP1  |  CIPHER
2222  |  FDFT1  |  CIPHER
3044  |  HBBP1  |  CIPHER
10767  |  HBS1L  |  CIPHER
8690  |  JRKL  |  CIPHER
140733  |  MACROD2  |  CIPHER
80327  |  MAPRE1P1  |  CIPHER
375449  |  MAST4  |  CIPHER
140909  |  MTCO2P1  |  CIPHER
64111  |  NPVF  |  CIPHER
26578  |  OSTF1  |  CIPHER
91461  |  PKDCC  |  CIPHER
5481  |  PPID  |  CIPHER
5858  |  PZP  |  CIPHER
54715  |  RBFOX1  |  CIPHER
392193  |  RPL19P13  |  CIPHER
646417  |  RPL29P5  |  CIPHER
100131991  |  RPL29P8  |  CIPHER
6172  |  RPL41P5  |  CIPHER
100271380  |  RPS27P18  |  CIPHER
100128756  |  RPS7P9  |  CIPHER
100133054  |  RPS9P3  |  CIPHER
23231  |  SEL1L3  |  CIPHER
283537  |  SLC46A3  |  CIPHER
285195  |  SLC9A9  |  CIPHER
6489  |  ST8SIA1  |  CIPHER
148534  |  TMEM56  |  CIPHER
54765  |  TRIM44  |  CIPHER
100033408  |  VN2R20P  |  CIPHER
57829  |  ZP4  |  CIPHER
80339  |  PNPLA3  |  CIPHER;CTD_human
2952  |  GSTT1  |  CTD_human
7040  |  TGFB1  |  CTD_human
929  |  CD14  |  CTD_human
6720  |  SREBF1  |  CTD_human
1437  |  CSF2  |  CTD_human
2938  |  GSTA1  |  CTD_human
8517  |  IKBKG  |  CTD_human
7133  |  TNFRSF1B  |  CTD_human
100462725  |  NAFLD2  |  CTD_human
1586  |  CYP17A1  |  CTD_human
284217  |  LAMA1  |  CTD_human
5055  |  SERPINB2  |  CTD_human
3949  |  LDLR  |  CTD_human
2944  |  GSTM1  |  CTD_human
27087  |  B3GAT1  |  CTD_human
9370  |  ADIPOQ  |  CTD_human
100380876  |  NAFLD1  |  CTD_human
355  |  FAS  |  CTD_human
4780  |  NFE2L2  |  CTD_human
1636  |  ACE  |  CTD_human
506  |  ATP5B  |  CTD_human
23411  |  SIRT1  |  CTD_human
5897  |  RAG2  |  CTD_human
3976  |  LIF  |  CTD_human
3552  |  IL1A  |  CTD_human
3565  |  IL4  |  CTD_human
3562  |  IL3  |  CTD_human
949  |  SCARB1  |  CTD_human
7494  |  XBP1  |  CTD_human
5244  |  ABCB4  |  CTD_human
53345  |  TM6SF2  |  CTD_human
2147  |  F2  |  CTD_human
5467  |  PPARD  |  CTD_human
5465  |  PPARA  |  CTD_human
3952  |  LEP  |  CTD_human
2950  |  GSTP1  |  CTD_human
4312  |  MMP1  |  CTD_human
8614  |  STC2  |  CTD_human
5551  |  PRF1  |  CTD_human
Text Mined Gene(Waiting for update.)
Locus(Waiting for update.)
Disease ID 881
Disease non-alcoholic fatty liver disease
Integrated Phenotype(Waiting for update.)
Text Mined Phenotype
HPO | Name | Sentences' Count(Total Phenotypes:91)
HP:0001513  |  Obesity  |  173
HP:0000855  |  Insulin resistance  |  157
HP:0001397  |  Hepatic steatosis  |  96
HP:0000819  |  Diabetes mellitus  |  37
HP:0002621  |  Atherosclerosis  |  28
HP:0001394  |  Hepatic cirrhosis  |  24
HP:0001395  |  Hepatic fibrosis  |  19
HP:0012743  |  Central obesity  |  17
HP:0012115  |  Liver inflammation  |  15
HP:0001402  |  Hepatocellular carcinoma  |  13
HP:0001677  |  Coronary artery disease  |  13
HP:0003077  |  Hyperlipidemia  |  12
HP:0030731  |  Carcinoma  |  12
HP:0002910  |  Elevated transaminases  |  10
HP:0000822  |  Hypertension  |  10
HP:0000147  |  Sclerocystic ovaries  |  9
HP:0000821  |  Underactive thyroid  |  9
HP:0000833  |  Glucose intolerance  |  8
HP:0200123  |  Chronic liver inflammation  |  7
HP:0003074  |  High blood glucose  |  6
HP:0001081  |  Gallstones  |  5
HP:0003287  |  Abnormality of mitochondrial metabolism  |  5
HP:0100512  |  Vitamin D deficiency  |  5
HP:0002896  |  Liver cancer  |  5
HP:0001824  |  Weight loss  |  5
HP:0012622  |  Chronic kidney disease  |  5
HP:0002149  |  Hyperuricemia  |  5
HP:0001409  |  Portal hypertension  |  4
HP:0003765  |  Psoriasis  |  4
HP:0000488  |  Noninflammatory retina disease  |  3
HP:0000842  |  Elevated insulin level  |  3
HP:0002870  |  Obstructive sleep apnea  |  2
HP:0002020  |  Heartburn  |  2
HP:0001717  |  Coronary artery calcification  |  2
HP:0010535  |  Sleep apnea  |  2
HP:0001399  |  Liver failure  |  2
HP:0003002  |  Breast carcinoma  |  2
HP:0002155  |  Increased triglycerides  |  2
HP:0001548  |  Overgrowth  |  2
HP:0002908  |  Conjugated hyperbilirubinemia  |  1
HP:0008356  |  Combined hyperlipidaemia  |  1
HP:0009125  |  Lipodystrophy  |  1
HP:0004943  |  Accelerated atherosclerosis  |  1
HP:0003281  |  Increased ferritin  |  1
HP:0000824  |  Growth hormone deficiency  |  1
HP:0005202  |  Helicobacter pylori infection  |  1
HP:0200063  |  Colorectal polyposis  |  1
HP:0100724  |  Hypercoagulability  |  1
HP:0009800  |  gestational diabetes  |  1
HP:0100785  |  Insomnia  |  1
HP:0006562  |  Viral hepatitis  |  1
HP:0002189  |  Excessive daytime sleepiness  |  1
HP:0012594  |  High urine albumin levels  |  1
HP:0000112  |  Nephropathy  |  1
HP:0001297  |  Cerebral vascular events  |  1
HP:0005978  |  Noninsulin dependent diabetes mellitus  |  1
HP:0011123  |  Skin inflammation  |  1
HP:0006555  |  Diffuse hepatic steatosis  |  1
HP:0008282  |  Unconjugated hyperbilirubinemia  |  1
HP:0012197  |  Insulinoma  |  1
HP:0001712  |  Left ventricular hypertrophy  |  1
HP:0002608  |  Celiac disease  |  1
HP:0006279  |  Beta-cell dysfunction  |  1
HP:0000083  |  Renal insufficiency  |  1
HP:0006561  |  Lipid accumulation in hepatocytes  |  1
HP:0004929  |  Coronary artherosclerosis  |  1
HP:0004324  |  Increased body weight  |  1
HP:0000739  |  Anxiety  |  1
HP:0009830  |  Peripheral neuritis  |  1
HP:0002900  |  Hypokalemia  |  1
HP:0001414  |  Microvesicular hepatic steatosis  |  1
HP:0000716  |  Depression  |  1
HP:0000704  |  Pyorrhea  |  1
HP:0001410  |  Decreased liver function  |  1
HP:0001939  |  Laboratory abnormality  |  1
HP:0002904  |  High blood bilirubin levels  |  1
HP:0002076  |  Migraine headaches  |  1
HP:0001714  |  Ventricular hypertrophy  |  1
HP:0100896  |  Rectal polyps  |  1
HP:0001578  |  Hypercortisolism  |  1
HP:0001370  |  Rheumatoid arthritis  |  1
HP:0001518  |  Small for gestational age  |  1
HP:0002140  |  Ischemic stroke  |  1
HP:0003199  |  Decreased muscle mass  |  1
HP:0003774  |  End-stage renal failure  |  1
HP:0002104  |  Absence of spontaneous respiration  |  1
HP:0001907  |  Thromboembolic disease  |  1
HP:0002664  |  Neoplasia  |  1
HP:0001262  |  Somnolence  |  1
HP:0002960  |  Autoimmune condition  |  1
HP:0001511  |  Prenatal onset growth retardation  |  1
Disease ID 881
Disease non-alcoholic fatty liver disease
Manually Symptom(Waiting for update.)
Text Mined Symptom
UMLS | Name | Sentences' Count(Total Symptoms:22)
C0028754  |  obesity  |  21
C2711227  |  steatohepatitis  |  21
C0239946  |  liver fibrosis  |  20
C0948265  |  metabolic syndrome  |  18
C2711227  |  hepatic steatosis  |  12
C0011860  |  type 2 diabetes  |  11
C0239946  |  hepatic fibrosis  |  10
C0019204  |  hepatocellular carcinoma  |  6
C0004153  |  atherosclerosis  |  5
C0427008  |  stiffness  |  5
C0577631  |  carotid atherosclerosis  |  4
C0007222  |  cardiovascular disease  |  3
C0023895  |  liver disease  |  3
C0242339  |  dyslipidemia  |  3
C0159069  |  impaired glucose tolerance  |  3
C0520679  |  obstructive sleep apnea  |  2
C0023890  |  cirrhosis  |  2
C0019158  |  hepatitis  |  2
C0007570  |  celiac disease  |  1
C0007570  |  coeliac disease  |  1
C2711227  |  liver steatosis  |  1
C0085605  |  liver failure  |  1
Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)
Text Mining Genotype(Total Genotypes:0)
(Waiting for update.)
All Snps(Total Genotypes:167)
snpId pubmedId geneId geneSymbol diseaseId sourceId sentence score Year geneSymbol_dbSNP CHROMOSOME POS REF ALT
rs1095466820708005781CACNA2D1umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010CACNA2D1782218335GA
rs11083271207080051000CDH2umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010NA1828346095CT
rs1131580240656848743TNFSF10umls:C0400966BeFreeWe recently discovered the association of nonalcoholic fatty liver disease, a risk factor for T2DM, with a single nucleotide polymorphism (SNP) in the TRAIL (TNFSF10) gene at site 1595C/T (rs1131580), indicating the possible association of T2DM with this TRAIL polymorphism.0.0005428842014TNFSF103172505830AG
rs113710023278404127069OR2T10umls:C0400966BeFreeWe observed a significant association between the LEPR rs1137100 and rs1137101 with susceptibility to NAFLD (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.18-2.28, P = 0.003; and OR 1.61, 95% CI 1.11-2.34, P = 0.013, respectively) and to non-alcoholic steatohepatitis (OR 1.49, 95% CI 1.05-2.12, P = 0.026; and OR 1.57, 95% CI 1.05-2.35, P = 0.029, respectively).0.0002714422013LEPR165570758AG
rs113710123278404127069OR2T10umls:C0400966BeFreeWe observed a significant association between the LEPR rs1137100 and rs1137101 with susceptibility to NAFLD (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.18-2.28, P = 0.003; and OR 1.61, 95% CI 1.11-2.34, P = 0.013, respectively) and to non-alcoholic steatohepatitis (OR 1.49, 95% CI 1.05-2.12, P = 0.026; and OR 1.57, 95% CI 1.05-2.35, P = 0.029, respectively).0.0002714422013LEPR165592830AG
rs116695922070800560680CELF5umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010NA193318512AG
rs121378552447704279660PPP1R3Bumls:C0400966BeFreeBy studying the genetic variants of obese Taiwanese children, we confirmed that the genetic variants in GCKR rs780094 and PNPLA3 rs738409, but not in NCAN rs2228603, LYPLAL1 rs12137855, and PPP1R3B rs4240624, are associated with an increased risk of NAFLD.0.0008143262014LOC1019297131219275036CT
rs1213785524477042127018LYPLAL1umls:C0400966BeFreeBy studying the genetic variants of obese Taiwanese children, we confirmed that the genetic variants in GCKR rs780094 and PNPLA3 rs738409, but not in NCAN rs2228603, LYPLAL1 rs12137855, and PPP1R3B rs4240624, are associated with an increased risk of NAFLD.0.0005428842014LOC1019297131219275036CT
rs121908277210571637124TNFumls:C0400966BeFreeG308A polymorphism of TNF-alpha gene is associated with insulin resistance and histological changes in non alcoholic fatty liver disease patients.0.0035287442010INS;INS-IGF2112159877TC
rs1227756207080051305COL13A1umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010COL13A11069828748GA
rs123444882070800526578OSTF1umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010NA975811009GA
rs12970134244582184160MC4Rumls:C0400966BeFreeThe FTO rs9939609 A-allele increased risk of NAFLD and MC4R rs12970134 was associated with ALT level through an effect on BMI.0.0002714422015NA1860217517GA
rs129701342445821879068FTOumls:C0400966BeFreeThe FTO rs9939609 A-allele increased risk of NAFLD and MC4R rs12970134 was associated with ALT level through an effect on BMI.0.0002714422015NA1860217517GA
rs129701342445821851141INSIG2umls:C0400966BeFreeOur aim was to identify whether the obesity-susceptible gene variants (rs9939609, rs9930506, and rs4783819 in fat mass and obesity-associated gene (FTO); rs12970134 and rs17782313 in melanocortin-4 receptor gene (MC4R); and rs7566605, rs13428113, and rs9308762 in insulin-induced gene 2 [INSIG2]) were associated with NAFLD.0.0002714422015NA1860217517GA
rs130508820708005283537SLC46A3umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010SLC46A3;RNU6-53P1328704313TC
rs134128522215792423175LPIN1umls:C0400966BeFreeLPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease.0.0002714422012LPIN1211774815CT
rs134281132445821851141INSIG2umls:C0400966BeFreeOur aim was to identify whether the obesity-susceptible gene variants (rs9939609, rs9930506, and rs4783819 in fat mass and obesity-associated gene (FTO); rs12970134 and rs17782313 in melanocortin-4 receptor gene (MC4R); and rs7566605, rs13428113, and rs9308762 in insulin-induced gene 2 [INSIG2]) were associated with NAFLD.0.0002714422015INSIG2;LOC1053739882118089309TC
rs141489620708005148534TMEM56umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010TMEM56-RWDD3;LOC101928118195226754GA
rs169713720009918375449MAST4umls:C0400966GAD[These results suggest that in the context of HIV infection and HAART, a functional SNP in a biologically plausible candidate gene, RYR3, is associated with increased common carotid IMT, which is a surrogate for atherosclerosis.]0.0023670322010MAST4567156347GA
rs171519042000991864111NPVFumls:C0400966GAD[These results suggest that in the context of HIV infection and HAART, a functional SNP in a biologically plausible candidate gene, RYR3, is associated with increased common carotid IMT, which is a surrogate for atherosclerosis.]0.0023670322010NA725568789GA
rs177823132445821851141INSIG2umls:C0400966BeFreeOur aim was to identify whether the obesity-susceptible gene variants (rs9939609, rs9930506, and rs4783819 in fat mass and obesity-associated gene (FTO); rs12970134 and rs17782313 in melanocortin-4 receptor gene (MC4R); and rs7566605, rs13428113, and rs9308762 in insulin-induced gene 2 [INSIG2]) were associated with NAFLD.0.0002714422015NA1860183864TC
rs1799945207390793077HFEumls:C0400966BeFreeThe aim of this study was to assess whether a panel of genetic variants previously reported to influence iron metabolism, including the C282Y/H63D HFE, the PiZ/PiS alpha1-antitrypsin, the IVS1-24 ferroportin polymorphisms, and the beta-thalassemia trait, may be able to predict the presence of parenchymal siderosis and of progressive fibrosis in NAFLD.0.0032573022010HFE626090951CG
rs1800206238918245468PPARGumls:C0400966BeFreeThe objective of this study was to analyze the polymorphisms Leu162Val of PPARα and Pro12Ala of PPARγ as genetic risk factors for the development and progression of NAFLD.0.0029858612013PPARA2246218377CG
rs1800206238918245465PPARAumls:C0400966BeFreeThe objective of this study was to analyze the polymorphisms Leu162Val of PPARα and Pro12Ala of PPARγ as genetic risk factors for the development and progression of NAFLD.0.124343072013PPARA2246218377CG
rs1800234188539975465PPARAumls:C0400966BeFreeA Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio.0.124343072008PPARA2246219983TA,C
rs1800562127790713077HFEumls:C0400966BeFreeThe mild iron overload associated with heterozygosity for C282Y HFE mutation confers susceptibility to nonalcoholic fatty liver disease, causing relative insulin deficiency.0.0032573022003HFE626092913GA
rs18005622261104957817HAMPumls:C0400966BeFreeLower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.0.0005428842012HFE626092913GA
rs1800562207390793077HFEumls:C0400966BeFreeThe aim of this study was to assess whether a panel of genetic variants previously reported to influence iron metabolism, including the C282Y/H63D HFE, the PiZ/PiS alpha1-antitrypsin, the IVS1-24 ferroportin polymorphisms, and the beta-thalassemia trait, may be able to predict the presence of parenchymal siderosis and of progressive fibrosis in NAFLD.0.0032573022010HFE626092913GA
rs1800562226110493077HFEumls:C0400966BeFreeLower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.0.0032573022012HFE626092913GA
rs1800562239905223077HFEumls:C0400966BeFreeRESEARCH DESIGN AND METHODS We studied these 16 variables in 159 nonscreening hemochromatosis probands with HFE C282Y homozygosity: age; sex; BMI; diabetes reports in first-degree family members (dichotomous); heavy ethanol consumption; cigarette smoking; elevated serum alanine aminotransferase/aspartate aminotransferase levels; nonalcoholic fatty liver; chronic viral hepatitis; cirrhosis; hand arthropathy; iron removed by phlebotomy; and positivity for HLA-A*01, B*08; A*03, B*07; and A*03, B*14 haplotypes.0.0032573022015HFE626092913GA
rs1800591255012264490MT1Bumls:C0400966BeFreeIn this meta-analysis, we evaluated the relationships between a common polymorphism (-493G>T, rs1800591 G>T) in the MTP gene and NAFLD risk.0.0008143262015MTTP499574331GT
rs1800591245888004490MT1Bumls:C0400966BeFreeMany existing studies have demonstrated that a common polymorphism (-493G>T, rs1800591 G>T) in the MTP gene may be implicated in the development and progression of NAFLD, but individually published results are inconclusive.0.0008143262014MTTP499574331GT
rs1801282219397325468PPARGumls:C0400966BeFreePPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population.0.0029858612012PPARG312351626CG
rs1801282238918205468PPARGumls:C0400966BeFreeAssociation between the Pro12Ala polymorphism of PPAR-γ gene and the non-alcoholic fatty liver disease: a meta-analysis.0.0029858612013PPARG312351626CG
rs1801282238918245465PPARAumls:C0400966BeFreeThe objective of this study was to analyze the polymorphisms Leu162Val of PPARα and Pro12Ala of PPARγ as genetic risk factors for the development and progression of NAFLD.0.124343072013PPARG312351626CG
rs1801282238918245468PPARGumls:C0400966BeFreeThe objective of this study was to analyze the polymorphisms Leu162Val of PPARα and Pro12Ala of PPARγ as genetic risk factors for the development and progression of NAFLD.0.0029858612013PPARG312351626CG
rs1801282246975665468PPARGumls:C0400966BeFreeMeta-analysis of associations between the peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and susceptibility to nonalcoholic fatty liver disease, rheumatoid arthritis, and psoriatic arthritis.0.0029858612014PPARG312351626CG
rs1805094225303503953LEPRumls:C0400966BeFreeLys656Asn polymorphism of LEPR gene is associated with obesity parameters, insulin resistance and glucose levels in patients with NAFLD.0.0010857672012LEPR165610269GC
rs1805192219397325468PPARGumls:C0400966BeFreePPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population.0.0029858612012PPARG312379739CG
rs1805192238918205468PPARGumls:C0400966BeFreeAssociation between the Pro12Ala polymorphism of PPAR-γ gene and the non-alcoholic fatty liver disease: a meta-analysis.0.0029858612013PPARG312379739CG
rs1805192246975665468PPARGumls:C0400966BeFreeMeta-analysis of associations between the peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and susceptibility to nonalcoholic fatty liver disease, rheumatoid arthritis, and psoriatic arthritis.0.0029858612014PPARG312379739CG
rs1805192238918245465PPARAumls:C0400966BeFreeThe objective of this study was to analyze the polymorphisms Leu162Val of PPARα and Pro12Ala of PPARγ as genetic risk factors for the development and progression of NAFLD.0.124343072013PPARG312379739CG
rs1805192238918245468PPARGumls:C0400966BeFreeThe objective of this study was to analyze the polymorphisms Leu162Val of PPARα and Pro12Ala of PPARγ as genetic risk factors for the development and progression of NAFLD.0.0029858612013PPARG312379739CG
rs20143552003758935ACADSumls:C0400966GAD[A genome-wide perspective of genetic variation in human metabolism.]0.0023670322010ACADS12120737721TC
rs20730802271987629780PARVBumls:C0400966GWASCATGenetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.0.1205428842012PARVB2243998522CT
rs21435712271987625813SAMM50umls:C0400966GWASCATGenetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.0.1205428842012SAMM502243995806GA
rs2216228207080056489ST8SIA1umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010ST8SIA11222212901TC
rs2228314249921626721SREBF2umls:C0400966BeFreeRelationship of SREBP-2 rs2228314 G>C polymorphism with nonalcoholic fatty liver disease in a Han Chinese population.0.0019000932015SREBF22241880738GC
rs2228314221828106721SREBF2umls:C0400966BeFreeSREBP-2 1784 G/C genotype is associated with non-alcoholic fatty liver disease in north Indians.0.0019000932011SREBF22241880738GC
rs22286032447704279660PPP1R3Bumls:C0400966BeFreeBy studying the genetic variants of obese Taiwanese children, we confirmed that the genetic variants in GCKR rs780094 and PNPLA3 rs738409, but not in NCAN rs2228603, LYPLAL1 rs12137855, and PPP1R3B rs4240624, are associated with an increased risk of NAFLD.0.0008143262014NCAN1919219115CA,T
rs222860324477042127018LYPLAL1umls:C0400966BeFreeBy studying the genetic variants of obese Taiwanese children, we confirmed that the genetic variants in GCKR rs780094 and PNPLA3 rs738409, but not in NCAN rs2228603, LYPLAL1 rs12137855, and PPP1R3B rs4240624, are associated with an increased risk of NAFLD.0.0005428842014NCAN1919219115CA,T
rs2241766192469759370ADIPOQumls:C0400966BeFreeThe T45G and G276T of the adiponectin gene may not be the important determinants of NAFLD in Chinese people, but some of them still influence serum ALT, BMI, IR, lipid, glucose metabolism and plasma adiponectin concentration.0.2010857672008ADIPOQ;ADIPOQ-AS13186853103TG
rs22869632003758933ACADLumls:C0400966GAD[A genome-wide perspective of genetic variation in human metabolism.]0.0023670322010ACADL2210195326TG
rs24542062635670910891PPARGC1Aumls:C0400966BeFreeThe p.Ile1762Val substitution (TET2-rs2454206) was associated with liver PPARGC1A-methylation and transcriptional levels, and Type 2 diabetes.Our results suggest that 5-hmC might be involved in the pathogenesis of NAFLD by regulating liver mitochondrial biogenesis and PPARGC1A expression.0.0819000932015TET2;TET2-AS14105275794AG,T
rs24542062635670954790TET2umls:C0400966BeFreeThe p.Ile1762Val substitution (TET2-rs2454206) was associated with liver PPARGC1A-methylation and transcriptional levels, and Type 2 diabetes.Our results suggest that 5-hmC might be involved in the pathogenesis of NAFLD by regulating liver mitochondrial biogenesis and PPARGC1A expression.0.0002714422015TET2;TET2-AS14105275794AG,T
rs24996042070800557829ZP4umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010NA1237940201CT
rs2645424207080052222FDFT1umls:C0400966GAD[In multivariate models adjusted for age, body mass index, diabetes, waist/hip ratios, and levels of glycated hemoglobin, the NAFLD activity score was associated with the SNP rs2645424 on chromosome 8 in farnesyl diphosphate farnesyl transferase 1 (FDFT1) (P = 6.8 A 10(-7)).]0.0029099162010FDFT1811826954AG,C
rs2645424238700672222FDFT1umls:C0400966BeFreeRecently, a polymorphism of single nucleotide polymorphism SNP rs2645424 of farnesyl diphosphate farnesyl transferase 1 (FDFT1) was identified in NAFLD/NASH as a possible causal link to steatosis and fibrosis progression.0.0029099162013FDFT1811826954AG,C
rs2645424207080052222FDFT1umls:C0400966BeFreeIn multivariate models adjusted for age, body mass index, diabetes, waist/hip ratios, and levels of glycated hemoglobin, the NAFLD activity score was associated with the SNP rs2645424 on chromosome 8 in farnesyl diphosphate farnesyl transferase 1 (FDFT1) (P = 6.8 × 10(-7)).0.0029099162010FDFT1811826954AG,C
rs27108332070800591351DDX60Lumls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010NA4168488807TC
rs280020708005285195SLC9A9umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010SLC9A93143705980CT
rs28541162470715180339PNPLA3umls:C0400966BeFreeGenotypes for rs2854116 and rs2854117 in APOC3 and the known rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3) in 390 patients with NAFLD and 409 control subjects were determined by sequencing and polymerase chain reaction analysis.0.2648967072014APOC311116829453CT
rs285411621663607345APOC3umls:C0400966BeFreeApolipoprotein C3 (APOC3) is a component of triglyceride-rich lipoproteins, and APOC3 rs2854116 and rs2854117 polymorphisms have been associated with non-alcoholic fatty liver disease, hypertriglyceridaemia, and insulin-resistance.0.0024429772011APOC311116829453CT
rs28541172470715180339PNPLA3umls:C0400966BeFreeGenotypes for rs2854116 and rs2854117 in APOC3 and the known rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3) in 390 patients with NAFLD and 409 control subjects were determined by sequencing and polymerase chain reaction analysis.0.2648967072014APOC311116829426TC
rs285411721663607345APOC3umls:C0400966BeFreeApolipoprotein C3 (APOC3) is a component of triglyceride-rich lipoproteins, and APOC3 rs2854116 and rs2854117 polymorphisms have been associated with non-alcoholic fatty liver disease, hypertriglyceridaemia, and insulin-resistance.0.0024429772011APOC311116829426TC
rs28960192353591180339PNPLA3umls:C0400966GWASCATGenome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan.0.2648967072013PNPLA32243937814TG
rs37726272348403580339PNPLA3umls:C0400966BeFreeGene-gene interaction between the AGTR1 gene and the patatin-like phospholipase domain-containing 3 (PNPLA3) gene, which we previously reported as associated with NAFLD in this sample, showed a strong interaction between AGTR1 (rs3772627), AGTRI (rs3772630) and PNPLA3 (rs738409) polymorphisms on NAFLD susceptibility (p = 0.007).0.2648967072013AGTR13148712467AG
rs37726302348403580339PNPLA3umls:C0400966BeFreeGene-gene interaction between the AGTR1 gene and the patatin-like phospholipase domain-containing 3 (PNPLA3) gene, which we previously reported as associated with NAFLD in this sample, showed a strong interaction between AGTR1 (rs3772627), AGTRI (rs3772630) and PNPLA3 (rs738409) polymorphisms on NAFLD susceptibility (p = 0.007).0.2648967072013AGTR13148708685TC
rs386596107217568496648SOD2umls:C0400966BeFreeThe SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies.0.0002714422012NANANANANA
rs397507444235478294524MTHFRumls:C0400966BeFreeThe aim of this study was to investigate the relation between liver steatosis with plasma homocysteine level and MTHFR C677T and A1298C polymorphisms in Brazilian patients with NAFLD.0.0013572092013MTHFR111794407TG
rs397507444260319744524MTHFRumls:C0400966BeFreeMTHFR 677C/T and 1298A/C mutations and non-alcoholic fatty liver disease.0.0013572092015MTHFR111794407TG
rs424062424477042127018LYPLAL1umls:C0400966BeFreeBy studying the genetic variants of obese Taiwanese children, we confirmed that the genetic variants in GCKR rs780094 and PNPLA3 rs738409, but not in NCAN rs2228603, LYPLAL1 rs12137855, and PPP1R3B rs4240624, are associated with an increased risk of NAFLD.0.0005428842014LOC15727389326721GA
rs42406242447704279660PPP1R3Bumls:C0400966BeFreeBy studying the genetic variants of obese Taiwanese children, we confirmed that the genetic variants in GCKR rs780094 and PNPLA3 rs738409, but not in NCAN rs2228603, LYPLAL1 rs12137855, and PPP1R3B rs4240624, are associated with an increased risk of NAFLD.0.0008143262014LOC15727389326721GA
rs47838192445821851141INSIG2umls:C0400966BeFreeOur aim was to identify whether the obesity-susceptible gene variants (rs9939609, rs9930506, and rs4783819 in fat mass and obesity-associated gene (FTO); rs12970134 and rs17782313 in melanocortin-4 receptor gene (MC4R); and rs7566605, rs13428113, and rs9308762 in insulin-induced gene 2 [INSIG2]) were associated with NAFLD.0.0002714422015FTO1653782735GC
rs4880217568496648SOD2umls:C0400966BeFreeThe SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies.0.0002714422012SOD26159692840AG
rs49525901996161991461PKDCCumls:C0400966GAD[In this analysis we have identified new candidate regions related to atopy and suggest SGK493 as an atopy locus, although these results need further replication.]0.0023670322009PKDCC242049781CT
rs4997652535923026291FGF21umls:C0400966BeFreeThe single nucleotide polymorphism rs499765 is associated with fibroblast growth factor 21 and nonalcoholic fatty liver disease in a Chinese population with normal glucose tolerance.0.0016286512014NA1948763133CG
rs58542926254572093630INSumls:C0400966BeFreeCirculating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.0.0084146982014TM6SF21919268740CT
rs585429262530278180339PNPLA3umls:C0400966BeFreeA discrete trait analysis of NAFLD showed that rs58542926 was associated with a modest risk of fatty liver (P = 0.038; odds ratio [OR]: 1.37; 95% confidence interval [CI]: 1.02-1.84); nevertheless, conditioning on patatin-like phospholipase domain-containing 3 (PNPLA3)-rs738409 abolished this effect.0.2648967072014TM6SF21919268740CT
rs585429262576360753345TM6SF2umls:C0400966BeFreeHere we aimed to investigate the contribution of DNL to liver fat accumulation in the PNPLA3 I148M or TM6SF2 E167K genetic determinants of NAFLD.0.1216286512015TM6SF21919268740CT
rs585429262576360780339PNPLA3umls:C0400966BeFreeHere we aimed to investigate the contribution of DNL to liver fat accumulation in the PNPLA3 I148M or TM6SF2 E167K genetic determinants of NAFLD.0.2648967072015TM6SF21919268740CT
rs585429262582048453345TM6SF2umls:C0400966BeFreeThe TM6SF2 E167K variant was genotyped by TaqMan assays, steatosis graded according to the nonalcoholic fatty liver disease activity score, and necroinflammation and fibrosis graded and staged according to Ishak in Italian, and to Metavir in Swiss/German patients.0.1216286512015TM6SF21919268740CT
rs585429262545720953345TM6SF2umls:C0400966BeFreeCirculating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.0.1216286512014TM6SF21919268740CT
rs585429262497890353345TM6SF2umls:C0400966BeFreeTM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.0.1216286512014TM6SF21919268740CT
rs607939520708005140733MACROD2umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010MACROD22014347253GA
rs64360820708005100126693LINC00322umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010NA2143348682CT
rs6487679207080055858PZPumls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010NA129218736CT
rs659118220708005254102EHBP1L1umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010EHBP1L11165582285TG
rs6700896222155353952LEPumls:C0400966BeFreeThis study was designed to assess the role of soluble leptin and LepRb in NAFLD and to investigate whether leptin receptor gene (LepR) single nucleotide polymorphism (SNP; ID rs6700896) influences NAFLD complicated with or without type 2 diabetes mellitus (T2DM).0.1210857672012LEPR165624099CT
rs67439311987510385009MGC16025umls:C0400966GAD[Although our findings require replication and validation, this study demonstrates the potential of genomewide association studies to discover genes and pathways that mediate adverse effects of antipsychotics.]0.0023670322010NA2239496966GA
rs69825022438935910221TRIB1umls:C0400966BeFreeA TRIB1 SNP, rs6982502, was identified in an enhancer sequence, modulated enhancer activity in reporter gene assays, and was significantly (P=9.39 × 10(-7)) associated with ultrasonographically diagnosed non-alcoholic fatty liver disease in a population of 5570 individuals.0.0005428842014LOC1053757458125467120CT
rs7077164207080051305COL13A1umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010COL13A11069823442CT
rs7384092302370580339PNPLA3umls:C0400966BeFreeA genetic variant in PNPLA3 (PNPLA3(I148M)), a triacylglycerol (TAG) hydrolase, is a major risk factor for nonalcoholic fatty liver disease (NAFLD); however, the mechanism underlying this association is not known.0.2648967072012PNPLA32243928847CG
rs7384092470715180339PNPLA3umls:C0400966BeFreeGenotypes for rs2854116 and rs2854117 in APOC3 and the known rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3) in 390 patients with NAFLD and 409 control subjects were determined by sequencing and polymerase chain reaction analysis.0.2648967072014PNPLA32243928847CG
rs7384092279229580339PNPLA3umls:C0400966BeFreeWe aimed at studying the potential impact of the NAFLD-associated PNPLA3 rs738409 G-allele on NAFLD-related metabolic traits in hyperglycaemic individuals.0.2648967072012PNPLA32243928847CG
rs7384092384955480339PNPLA3umls:C0400966BeFreeThis study explicated symptoms in persons with NAFLD at higher risk of disease progression defined as the presence of one or two copies of the PNPLA3 (rs738409)-G allele.0.2648967072013PNPLA32243928847CG
rs7384092142371980339PNPLA3umls:C0400966GWASCATIn comparisons with 1,405 healthy controls from the Myocardial Genetics Consortium (MIGen), we observe significant associations with histologic NAFLD at variants in or near NCAN, GCKR, LYPLAL1, and PNPLA3, but not PPP1R3B.0.2648967072011PNPLA32243928847CG
rs7384091952457980339PNPLA3umls:C0400966BeFreeOur aims were to develop a method to accurately predict non-alcoholic fatty liver disease (NAFLD) and liver fat content based on routinely available clinical and laboratory data and to test whether knowledge of the recently discovered genetic variant in the PNPLA3 gene (rs738409) increases accuracy of the prediction.0.2648967072009PNPLA32243928847CG
rs7384092166550980339PNPLA3umls:C0400966BeFreeNon-alcoholic fatty liver disease (NAFLD) is commonly diagnosed in patients with obesity and type 2 diabetes mellitus (T2DM), and has been associated with the single nucleotide polymorphism (SNP) rs738409 in the PNPLA3 gene.0.2648967072011PNPLA32243928847CG
rs7384092447704279660PPP1R3Bumls:C0400966BeFreeBy studying the genetic variants of obese Taiwanese children, we confirmed that the genetic variants in GCKR rs780094 and PNPLA3 rs738409, but not in NCAN rs2228603, LYPLAL1 rs12137855, and PPP1R3B rs4240624, are associated with an increased risk of NAFLD.0.0008143262014PNPLA32243928847CG
rs7384092037336880339PNPLA3umls:C0400966BeFreeInherited factors play a major role in the predisposition to nonalcoholic fatty liver disease (NAFLD), and the rs738409 C-->G polymorphism of PNPLA3/adiponutrin, encoding for the isoleucine-to-methionine substitution at residue 148 (I148M) protein variant, has recently been recognized as a major determinant of liver fat content.0.2648967072010PNPLA32243928847CG
rs7384092351077980339PNPLA3umls:C0400966BeFreeRecently, a PNPLA3 gene variant (I148M) was strongly associated with NAFLD and higher ALT levels in obese adults, including Hispanics.0.2648967072013PNPLA32243928847CG
rs7384092003493380339PNPLA3umls:C0400966BeFreeA sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis.0.2648967072010PNPLA32243928847CG
rs7384092460762680339PNPLA3umls:C0400966BeFreeCarriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.0.2648967072014PNPLA32243928847CG
rs7384092506957280339PNPLA3umls:C0400966BeFreeRole of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.0.2648967072014PNPLA32243928847CG
rs7384092286915780339PNPLA3umls:C0400966BeFreeThe single nucleotide polymorphism (SNP) rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is associated with hepatic fat accumulation and disease progression in patients with non-alcoholic fatty liver disease and alcoholic liver disease (ALD).0.2648967072013PNPLA32243928847CG
rs7384092326981880339PNPLA3umls:C0400966BeFreePNPLA3 rs738409 increased the OR of NAFLD by 1.622 (95% CI: 1.071, 2.457; P = 0.023) in subjects with GC alleles and 2.659 (95% CI: 1.509, 4.686; P < 0.001) for GG alleles, as compared with CC alleles.0.2648967072013PNPLA32243928847CG
rs7384092189369880339PNPLA3umls:C0400966BeFreeRecently the common adiponutrin (PNPLA3) polymorphism p.I148M has been identified as a genetic determinant of severe forms of non-alcoholic fatty liver disease and alcoholic liver disease.0.2648967072011PNPLA32243928847CG
rs7384092468909480339PNPLA3umls:C0400966BeFreeThe common PNPLA3 (adiponutrin) variant p.I148M represents a major genetic driver of progression in non-alcoholic fatty liver disease (NAFLD).0.2648967072015PNPLA32243928847CG
rs7384092117616980339PNPLA3umls:C0400966BeFreeAssociation of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease.0.2648967072010PNPLA32243928847CG
rs7384092211005380339PNPLA3umls:C0400966BeFreeRegarding the latter, a sequence variation within the gene coding for patatin-like phospholipase encoding 3 (PNPLA3, rs738409) was found to modulate steatosis, necroinflammation and fibrosis in NAFLD.0.2648967072012PNPLA32243928847CG
rs7384092494777080339PNPLA3umls:C0400966BeFreeThe aim was to describe the different clinical presentations of non-alcoholic fatty liver disease on the basis of the patatin-like phospholipase domain-containing protein3 (PNPLA3) rs738409 gene variant.0.2648967072014PNPLA32243928847CG
rs7384092441725080339PNPLA3umls:C0400966BeFreeThe G allele in PNPLA3 rs738409 increases the risk of NAFLD in the general population, especially in subjects without metabolic syndrome, independent of dietary pattern and metabolic factors.0.2648967072013PNPLA32243928847CG
rs7384092317667480339PNPLA3umls:C0400966BeFreeA nonsynonymous single nucleotide polymorphism rs738409 (I148M) in patatin-like phospholipase domain-containing protein 3 (PNPLA3) predisposes susceptibility to NAFLD; however, its association with steatosis grade is inconsistent in the literature.0.2648967072012PNPLA32243928847CG
rs7384092348403580339PNPLA3umls:C0400966BeFreeGene-gene interaction between the AGTR1 gene and the patatin-like phospholipase domain-containing 3 (PNPLA3) gene, which we previously reported as associated with NAFLD in this sample, showed a strong interaction between AGTR1 (rs3772627), AGTRI (rs3772630) and PNPLA3 (rs738409) polymorphisms on NAFLD susceptibility (p = 0.007).0.2648967072013PNPLA32243928847CG
rs7384092613658780339PNPLA3umls:C0400966BeFreePNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity.0.2648967072015PNPLA32243928847CG
rs7384092580107680339PNPLA3umls:C0400966BeFreeThe PNPLA3/Adiponutrin rs738409 C/G single nucleotide polymorphism is associated with the severity of steatosis, steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease, as well as the severity of steatosis and fibrosis in patients with chronic hepatitis C (CHC).0.2648967072015PNPLA32243928847CG
rs7384092326981810891PPARGC1Aumls:C0400966BeFreeThe PPARGC1A rs8192678 risk A allele is associated with an increased risk of NAFLD, independent of the effect of the PNPLA3 rs738409 polymorphism in our population of obese Taiwanese children.0.0819000932013PNPLA32243928847CG
rs7384092593972080339PNPLA3umls:C0400966BeFreeObesity is associated with non-alcoholic fatty liver disease (NAFLD), and the patatin-like phospholipase 3 (PNPLA3) rs738409 (Ile148Met, C>G) gene polymorphism is one of the most important genetic determinants of NAFLD.0.2648967072015PNPLA32243928847CG
rs7384092341808580339PNPLA3umls:C0400966BeFreeIn this study, we investigated the interactions of PNPLA3 rs738409 with a broad panel of metabolic and histologic characteristics of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH) in patients with medically complicated obesity.0.2648967072012PNPLA32243928847CG
rs7384092138106880339PNPLA3umls:C0400966BeFreeMeta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.0.2648967072011PNPLA32243928847CG
rs7384092288429980339PNPLA3umls:C0400966BeFreeRecently, a sequence variation within the gene encoding for patatin-like phospholipase containing 3 (PNPLA3, rs738409) was found to modulate steatosis, inflammation and fibrosis in NAFLD.0.2648967072013PNPLA32243928847CG
rs7384092174528280339PNPLA3umls:C0400966BeFreeThe PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.0.2648967072011PNPLA32243928847CG
rs7384092391373180339PNPLA3umls:C0400966BeFreeThe aim of the study was to determine whether increased adipocyte size is associated with increased liver fat content due to nonalcoholic fatty liver disease (NAFLD) in humans independent of obesity, fat distribution and genetic variation in the patatin-like phospholipase domain-containing 3 gene (PNPLA3; adiponutrin) at rs738409.0.2648967072014PNPLA32243928847CG
rs73840924009255404663LINC01194umls:C0400966BeFree'PNPLA3 NAFLD' is associated with a relative deficiency of TAGs, supporting the idea that the I148M variant impedes intrahepatocellular lipolysis rather than stimulates TAG synthesis.0.0002714422014PNPLA32243928847CG
rs7384092187862080339PNPLA3umls:C0400966BeFreeExpression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease.0.2648967072011PNPLA32243928847CG
rs7384092576360753345TM6SF2umls:C0400966BeFreeHere we aimed to investigate the contribution of DNL to liver fat accumulation in the PNPLA3 I148M or TM6SF2 E167K genetic determinants of NAFLD.0.1216286512015PNPLA32243928847CG
rs7384092271987680339PNPLA3umls:C0400966GWASCATGenetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.0.2648967072012PNPLA32243928847CG
rs7384092142371980339PNPLA3umls:C0400966GAD[In comparisons with 1,405 healthy controls from the Myocardial Genetics Consortium (MIGen), we observe significant associations with histologic NAFLD at variants in or near NCAN, GCKR, LYPLAL1, and PNPLA3, but not PPP1R3B.]0.2648967072011PNPLA32243928847CG
rs7384092576360780339PNPLA3umls:C0400966BeFreeHere we aimed to investigate the contribution of DNL to liver fat accumulation in the PNPLA3 I148M or TM6SF2 E167K genetic determinants of NAFLD.0.2648967072015PNPLA32243928847CG
rs7384092562471280339PNPLA3umls:C0400966BeFreePNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.0.2648967072014PNPLA32243928847CG
rs7384092174528680339PNPLA3umls:C0400966BeFreeThe PNPLA3 rs738409 C>G polymorphism has been found to be strongly associated with non-alcoholic fatty liver disease and with alcoholic liver disease.0.2648967072011PNPLA32243928847CG
rs7384092564632880339PNPLA3umls:C0400966BeFreeA single nucleotide polymorphism (SNP) of the patatin-like phospholipase-3 (PNPLA3)/adiponutrin gene (rs738409 C>G) is strongly associated with nonalcoholic fatty liver disease; to our knowledge, no data are available on the impact of this PNPLA3 SNP on liver and metabolic outcomes during pregnancy in patients with gestational diabetes (GD).0.2648967072015PNPLA32243928847CG
rs7384092564174480339PNPLA3umls:C0400966BeFreePNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis.0.2648967072014PNPLA32243928847CG
rs73840924477042127018LYPLAL1umls:C0400966BeFreeBy studying the genetic variants of obese Taiwanese children, we confirmed that the genetic variants in GCKR rs780094 and PNPLA3 rs738409, but not in NCAN rs2228603, LYPLAL1 rs12137855, and PPP1R3B rs4240624, are associated with an increased risk of NAFLD.0.0005428842014PNPLA32243928847CG
rs7384092529031380339PNPLA3umls:C0400966BeFreeAssociation between the PNPLA3 I148M polymorphism and non-alcoholic fatty liver disease in the Uygur and Han ethnic groups of northwestern China.0.2648967072014PNPLA32243928847CG
rs7384092400925580339PNPLA3umls:C0400966BeFreeCirculating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.0.2648967072014PNPLA32243928847CG
rs7384092530278180339PNPLA3umls:C0400966BeFreeA discrete trait analysis of NAFLD showed that rs58542926 was associated with a modest risk of fatty liver (P = 0.038; odds ratio [OR]: 1.37; 95% confidence interval [CI]: 1.02-1.84); nevertheless, conditioning on patatin-like phospholipase domain-containing 3 (PNPLA3)-rs738409 abolished this effect.0.2648967072014PNPLA32243928847CG
rs7384092407436080339PNPLA3umls:C0400966BeFreeThe I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease.0.2648967072014PNPLA32243928847CG
rs7384092289848880339PNPLA3umls:C0400966BeFreeThe I148M PNPLA3 variant is associated with adiponectin levels in patients with NAFLD and in healthy subjects, but in the presence of adiponectin resistance not in CHC patients.0.2648967072012PNPLA32243928847CG
rs7384092064847480339PNPLA3umls:C0400966BeFreeI148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.0.2648967072010PNPLA32243928847CG
rs7384092148807580339PNPLA3umls:C0400966BeFreeA recent genome-wide association study identified a genetic variant in the patatin-like phospholipase-3 (PNPLA3) gene (rs738409 C>G) associated with steatosis that was further demonstrated to influence severity of fibrosis in nonalcoholic fatty liver disease.0.2648967072011PNPLA32243928847CG
rs75666052445821851141INSIG2umls:C0400966BeFreeOur aim was to identify whether the obesity-susceptible gene variants (rs9939609, rs9930506, and rs4783819 in fat mass and obesity-associated gene (FTO); rs12970134 and rs17782313 in melanocortin-4 receptor gene (MC4R); and rs7566605, rs13428113, and rs9308762 in insulin-induced gene 2 [INSIG2]) were associated with NAFLD.0.0002714422015LOC1053739882118078449CG
rs763229920708005285195SLC9A9umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010SLC9A93143337625GA
rs7664322018392953335BCL11Aumls:C0400966GAD[A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E.]0.0023670322010BCL11A260492835CA
rs7800942447704279660PPP1R3Bumls:C0400966BeFreeBy studying the genetic variants of obese Taiwanese children, we confirmed that the genetic variants in GCKR rs780094 and PNPLA3 rs738409, but not in NCAN rs2228603, LYPLAL1 rs12137855, and PPP1R3B rs4240624, are associated with an increased risk of NAFLD.0.0008143262014GCKR227518370TC
rs780094251677862646GCKRumls:C0400966BeFreeAlthough studies have suggested that rs780094, a common variant in the glucokinase regulatory (GCKR) gene to be associated with type 2 diabetes, obesity, and their related traits, the genetic basis of the association between GCKR rs780094 and nonalcoholic fatty liver disease (NAFLD) is still being examined.0.0019000932014GCKR227518370TC
rs78009425167786441911OR10J3umls:C0400966BeFreeOverall, the pooled result indicated that the GCKR rs780094 was significantly associated with increased risk of NAFLD (additive: odds ratio (OR) 1.25, 95% confidence interval (CI) 1.14-1.36, P < 0.00001).0.0002714422014GCKR227518370TC
rs78009424477042127018LYPLAL1umls:C0400966BeFreeBy studying the genetic variants of obese Taiwanese children, we confirmed that the genetic variants in GCKR rs780094 and PNPLA3 rs738409, but not in NCAN rs2228603, LYPLAL1 rs12137855, and PPP1R3B rs4240624, are associated with an increased risk of NAFLD.0.0005428842014GCKR227518370TC
rs780094251677862645GCKumls:C0400966BeFreeCommon variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis.0.0008143262014GCKR227518370TC
rs79287941987510354765TRIM44umls:C0400966GAD[Although our findings require replication and validation, this study demonstrates the potential of genomewide association studies to discover genes and pathways that mediate adverse effects of antipsychotics.]0.0023670322010TRIM441135679688AC
rs809991722257210282617IFNL3umls:C0400966BeFreeNo significant differences were found in allelic and genotypic frequencies of rs8099917 IL28B gene polymorphism between NAFLD subjects and controls.0.0008143262012NA1939252525TG
rs81926782360225110891PPARGC1Aumls:C0400966BeFreeAlthough clinical evidence suggests that Gly482Ser polymorphism of PGC-1α is associated with an increased incidence of nonalcoholic fatty liver disease, a direct role for Gly482Ser mutation in altering PGC-1α actions on hepatocyte fat deposition remains to be explored.0.0819000932013PPARGC1A423814039CT
rs81926782326981810891PPARGC1Aumls:C0400966BeFreeThe PPARGC1A rs8192678 risk A allele is associated with an increased risk of NAFLD, independent of the effect of the PNPLA3 rs738409 polymorphism in our population of obese Taiwanese children.0.0819000932013PPARGC1A423814039CT
rs8396200375895481PPIDumls:C0400966GAD[A genome-wide perspective of genetic variation in human metabolism.]0.0023670322010PPID4158709665TC
rs85579123144979164656TMPRSS6umls:C0400966BeFreeThe A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.0.0002714422012TMPRSS62237066896AT,G
rs8873042070800584766CRACR2Aumls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010CRACR2A123648382TC
rs894177207080059435CHST2umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010NA3143175569GA
rs93028411987510354715RBFOX1umls:C0400966GAD[Although our findings require replication and validation, this study demonstrates the potential of genomewide association studies to discover genes and pathways that mediate adverse effects of antipsychotics.]0.0023670322010RBFOX1167177121TA
rs93087622445821851141INSIG2umls:C0400966BeFreeOur aim was to identify whether the obesity-susceptible gene variants (rs9939609, rs9930506, and rs4783819 in fat mass and obesity-associated gene (FTO); rs12970134 and rs17782313 in melanocortin-4 receptor gene (MC4R); and rs7566605, rs13428113, and rs9308762 in insulin-induced gene 2 [INSIG2]) were associated with NAFLD.0.0002714422015INSIG22118106298CT
rs93760922018392910767HBS1Lumls:C0400966GAD[A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E.]0.0023670322010LOC1053780106135106006CA
rs95848052070800510160FARP1umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010FARP11398341776AG
rs9599032070800523231SEL1L3umls:C0400966GAD[A GWAS significantly associated genetic variants with features of hepatic histology in patients with NAFLD. These findings should be validated in larger and more diverse cohorts.]0.0023670322010SEL1L3425808474GA
rs99305062445821851141INSIG2umls:C0400966BeFreeOur aim was to identify whether the obesity-susceptible gene variants (rs9939609, rs9930506, and rs4783819 in fat mass and obesity-associated gene (FTO); rs12970134 and rs17782313 in melanocortin-4 receptor gene (MC4R); and rs7566605, rs13428113, and rs9308762 in insulin-induced gene 2 [INSIG2]) were associated with NAFLD.0.0002714422015FTO1653796553AG
rs99396092445821851141INSIG2umls:C0400966BeFreeOur aim was to identify whether the obesity-susceptible gene variants (rs9939609, rs9930506, and rs4783819 in fat mass and obesity-associated gene (FTO); rs12970134 and rs17782313 in melanocortin-4 receptor gene (MC4R); and rs7566605, rs13428113, and rs9308762 in insulin-induced gene 2 [INSIG2]) were associated with NAFLD.0.0002714422015FTO1653786615TA
rs99396092445821879068FTOumls:C0400966BeFreeThe FTO rs9939609 A-allele increased risk of NAFLD and MC4R rs12970134 was associated with ALT level through an effect on BMI.0.0002714422015FTO1653786615TA
rs9939609244582184160MC4Rumls:C0400966BeFreeThe FTO rs9939609 A-allele increased risk of NAFLD and MC4R rs12970134 was associated with ALT level through an effect on BMI.0.0002714422015FTO1653786615TA
GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)
GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)
Mapped by lexical matching(Total Items:0)
(Waiting for update.)
Mapped by homologous gene(Total Items:0)
(Waiting for update.)
Disease ID 881
Disease non-alcoholic fatty liver disease
Case(Waiting for update.)